SS

Sangarappan Sivakumar

Active Director Director DIN 07640602
DIN 07640602 First appointment Nov 2016 Primary industry Life Sciences
Unlock full profile Investments · shareholding · contact details
Current companies 6 active board seats
Past companies 3 historical roles
Total affiliations 9 Since Nov 2016
Shareholding value •••• Premium profile

About Sangarappan Sivakumar

Data last updated:

Sangarappan Sivakumar is a Director at Ssk Biosciences Private Limited (since 2021), Director at Ssk Materials Private Limited (since 2026) and Director at Pharmasyn Drugs & Intermediates Private Limited (since 2025), and holds 3 more current directorships. The companies operate in Life Sciences, Chemicals and Materials and Chemicals. The largest current company by reported revenue is Ssk Biosciences Private Limited at ₹49.41 Cr (FY 2025). Earlier, Sangarappan Sivakumar was a Director at Virupaksha Life Sciences Private Limited (2016–2018) and Director at Chembricks Laboratories Private Limited (2019–2020) and 1 more.

DIN 07640602
Primary Designation Director
Industry Life Sciences
First Appointment 15 Nov 2016
Oldest Company Age 13 yrs
Largest company Ssk Biosciences Private Limited · ₹49.41 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Ssk Biosciences Private Limited U74900TG2013PTC090263
Director12 Oct 20212013₹49.41 Cr (FY 2025)Active
Ssk Materials Private Limited U46521TS2026PTC220903
Director10 Aug 20262026Active
Director23 Feb 20252020Active
Sibira Pharma Private Limited U24239TG2022PTC166314
Director05 Sep 20222022Active
Designated Partner17 Sep 20212021Active
Partner07 Sep 20202020Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director15 Nov 20162016Converted To Llp
Director28 Mar 20192019₹16.6 Lakh (FY 2024)Active
Designated Partner16 Mar 20182018Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Brindavan Assets And Projects Llp
Ssk Infraprojects Llp
Sibira Pharma Private Limited
Ssk Biosciences Private Limited
Premium access

Shareholding and investment profile for Sangarappan Sivakumar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sangarappan Sivakumar

Sangarappan Sivakumar currently holds 6 directorships: Ssk Biosciences Private Limited (Director, since 12 Oct 2021, revenue ₹49.41 Cr (FY 2025)); Ssk Materials Private Limited (Director, since 10 Aug 2026); Pharmasyn Drugs & Intermediates Private Limited (Director, since 23 Feb 2025); Sibira Pharma Private Limited (Director, since 05 Sep 2022); Ssk Infraprojects Llp (Designated Partner, since 17 Sep 2021); and 1 more.

Sangarappan Sivakumar was first appointed on 15 Nov 2016 as Director at Virupaksha Life Sciences Private Limited. The most recent appointment on record is 10 Aug 2026 at Ssk Materials Private Limited.

Sangarappan Sivakumar held 3 earlier board appointments: Virupaksha Life Sciences Private Limited (Director, 15 Nov 2016 to 15 Mar 2018); Chembricks Laboratories Private Limited (Director, 28 Mar 2019 to 10 Nov 2020); Virupaksha Life Sciences Llp (Designated Partner, 16 Mar 2018 to 02 Nov 2020).

The current boards of Sangarappan Sivakumar's companies include Olli Sudar (Ssk Biosciences Private Limited), Ganga Bhavani Bandaru (Pharmasyn Drugs & Intermediates Private Limited), Bandi Chandana (Sibira Pharma Private Limited), Divya Balasubramanian (Sibira Pharma Private Limited), Payel Sarkar (Sibira Pharma Private Limited), Arulraj Louis Puthotta (Brindavan Assets And Projects Llp), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available